Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024

 

VANCOUVER, British Columbia, Radarseluma.Disway.Id,  -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, California April 5-10, 2024.

BACA JUGA: FIFGROUP Peduli Berbagi Takjil Menjelang Akhir Bulan Suci Ramadan

BACA JUGA:Terbaru Higgs Domino Global Bisa Login User Indonesia!

 

“Our team is looking forward to share new data from our strong portfolio of multispecific antibody therapeutics and antibody-drug conjugates including ZW191, an anticipated 2024 IND candidate,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “These data provide important new insights highlighting the potential of our candidates to represent major advances in the treatment of cancer while also demonstrating the potential to develop a new generation of novel antibody-drug conjugates and multispecific antibody therapeutics.”

 

Presentation Highlights

 

ZW191 - a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications

Abstract: 1862

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody-Based Technologies and New Inhibitors

 

Sumber: